-
In order to lay out the rehabilitation aid industry, this medical company is "buying and buying"
Time of Update: 2021-12-08
Regarding the acquisition of Acorn Trading by Corfu Medical, the industry believes that in addition to helping the former to create a series of posture correction, shaping, physiotherapy and wearable medical monitoring products based on medical technology, it will further improve the structure of rehabilitation products.
-
Emerging Internet giants frequently cross-border into the medical field, this time aiming at medical devices!
Time of Update: 2021-12-08
In recent years, with the intensification of aging and the rise of online medical care, medical devices seem to have become a new trend, and the number of industry companies is increasing .
-
The strategic layout of multinational pharmaceutical companies in China upgrades the new structure and major adjustments
Time of Update: 2021-12-07
It is reported that, in order to get closer to the needs of the Chinese market, Astellas established the Greater China region in April 2019, and carried out relevant reporting line upgrades and layout planning adjustments; and this strategic upgrade is the continuation and deepening of the company’s previous development strategy.
-
This blood products company is on the path of medical beauty
Time of Update: 2021-12-07
Xingkerong Pharmaceutical will develop polycaprolactone microsphere facial fillers for injection and its materials against the domestically marketed "girl needle" Ellansé, which has been officially put into commercial sales in August this year .
-
Gloria successfully passed the Hong Kong Stock Exchange listing hearing and expects to raise over US$1 billion
Time of Update: 2021-12-06
According to data, Kailaiying is a CDMO company, which mainly provides one-stop services and solutions throughout the life cycle of drug development and production .
137 billion yuan in revenue in 2020, with a compound annual growth rate of 31.
-
BeiGene ranks C in the innovative drug market and will soon become a listed pharmaceutical company in the "A+H+N" three places
Time of Update: 2021-12-06
In early 2021, BeiGene submitted a prospectus to the Science and Technology Innovation Board, and plans to raise 20 billion yuan .
02 billion yuan, net loss attributable to shareholders of the parent company is 8.
-
This biotech company intends to spin off its pharmaceutical business and focus on its three main businesses
Time of Update: 2021-12-06
It is reported that after the completion of this transaction, VTR will divest its steroid hormone API related business, and the funds obtained from the sale of assets are expected to be used to increase investment in the three main businesses of biological enzyme preparations, plant extracts, animal nutrition and health And industrial upgrading .
-
Chinese scientists reveal that the H5N8 virus did not cause the outbreak of bird flu in China
Time of Update: 2021-12-05
The Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences announced on the 7th that the research team of Academician Chen Hualan found that the H5N8 virus (hereinafter referred to as "H5N8") that swept Europe and Asia last year was introduced into China through swans at the beginning of this year and did not cause poultry.
-
Home-made cervical cancer vaccine won the international "passport"
Time of Update: 2021-12-05
Breaking through the "99% bottleneck"-the domestic cervical cancer vaccine won the international "pass" October 14, 2021 is a memorable day, by the Xiamen University Xia Ningshao team and Yangshengtang Wantai Biotech's Xiamen The first domestic cervical cancer vaccine "Xinkening" jointly developed by Wantai Canghai Biotechnology Co.
-
In the field of tumor, Hengrui and CStone reached a strategic cooperation of 1.3 billion yuan
Time of Update: 2021-12-05
CStone Pharmaceuticals will grant Hengrui Medicine the exclusive right to develop, register, produce and commercialize the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region.
-
The domestic high-end intelligent interventional radiography system successfully completed clinical verification
Time of Update: 2021-12-05
The team of Academician Ge Junbo and Professor Yan Zhiping of Zhongshan Hospital Affiliated to Fudan University, and the team of Vice President Cheng Yingsheng of Shanghai Sixth People’s Hospital completed the first cases of cardiovascular intervention, tumor intervention, and cerebrovascular intervention on domestic high-end interventional radiography equipment.
-
2020 new drug registration clinical trial status report released
Time of Update: 2021-12-05
According to the phase analysis of new drug trials according to the type of drugs, phase I of chemical drugs and biological products account for a relatively large proportion, and clinical trials of traditional Chinese medicines are mainly phase II clinical trials .
-
217 million!
Time of Update: 2021-12-04
After the completion of this transaction, the target company will use an international management team, a sound legal system, and more A high-efficiency production line and expandable additional capacity space to undertake CDMO business for domestic and foreign customers .
-
China Resources Pharmaceuticals becomes the controlling shareholder of Boya Biology, or accelerates the cross-border blood product market
Time of Update: 2021-12-04
" The announcement shows that on November 17, the company has received the "Confirmation of Acceptance of Share Registration Application" issued by the Shenzhen Branch of China Clearing Corporation.
It is a holding company and announced that it has completed the transfer and registration procedures at the Shenzhen Branch of China Clearing Corporation .
-
CSPC is "chopping hands", and spends another billion yuan to increase the layout of innovative medicine field!
Time of Update: 2021-12-04
From the data, it can be seen that CSPC started from raw materials, but the company began to transform into innovative drugs very early.
However, after entering the medical insurance negotiations, the third quarter report of this year showed that Enbipu’s sales revenue decreased by 11.
-
Roche terminated cooperation with domestic diagnostic companies in order to adjust its strategic layout
Time of Update: 2021-12-03
According to Roche Pharmaceuticals, the establishment of the Chinese product pipeline strategy team is mainly to strengthen China's overall strategic layout, and to work closely with headquarters and all parties in the industry chain to benefit more patients in China .
-
Acoustic signal is expected to be used in proton scintillation therapy
Time of Update: 2021-12-02
With the advancement of proton beam technology, including FLASH flash therapy and the development of low-noise sensors, the team's research results are expected to be used clinically .
-
Drinking more coffee can prevent Alzheimer's disease
Time of Update: 2021-12-02
At the same time, higher coffee intake also seems to be related to slowing down the accumulation of amyloid in the brain, which is a key factor in the development of Alzheimer's disease .
-
Antihistamines can improve immunotherapy for cancer patients
Time of Update: 2021-12-02
Since H1 antihistamines can specifically block the binding of histamine to HRH1, the researchers linked the above findings to the results of experiments in mice, pointing out that histamine secreted by cancer and released by allergic reactions, as well as the high level of HRH1 in macrophages Expression inhibits the activation of cytotoxic T cells and confers resistance to immunotherapy, while antihistamines partially rescued all phenotypic mice .
-
Chinese scientists develop fast insulin control switch
Time of Update: 2021-12-02
Chinese scientists develop fast insulin control switch Chinese scientists develop rapid insulin control switches Chinese scientists develop rapid insulin control switches Recently, Peking University's School of Pharmacy researcher Liu Tao's group and East China Normal University's School of Life Sciences researcher Ye Haifeng's group have collaborated to develop a gene switch that quickly regulates insulin expression, providing new tools for synthetic biology and cell therapy research .
